Screener
Madrigal Pharmaceuticals, Inc. MDGL Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $292,726 | $198,693 |
| Restricted cash | 155 | 5,090 |
| Marketable securities | 546,027 | 784,866 |
| Trade receivables, net | 192,311 | 134,476 |
| Inventory | 99,391 | 74,841 |
| Prepaid expenses and other current assets | 68,570 | 47,804 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s restricted cash?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported restricted cash of $155K in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s restricted cash changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s restricted cash decreased by 96.9% year-over-year, from $5M to $155K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude